City Therapeutics, Inc. (NasdaqGM: CTY)
Health Care · Biotechnology · US
$16.64
-4.91% today · -25.7% 1Y
City Therapeutics, Inc. (NasdaqGM: CTY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $827.95M and employs 75 people.
Over the last twelve months the share price has lost 25.7%, trading between 16.41 and 23.88.
Tweenvest scores City Therapeutics, Inc. across four factors: quality 44/100, value 67/100. Its strongest factor is value.
CTY price history
Key figures
- Market cap
- $827.95M
- Revenue (TTM)
- $14.34M
- P/E
- -29.74
- EPS
- -12.46
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $23.88
- 52-week low
- $16.41
- Avg volume (3M)
- —
- Shares outstanding
- 49.76M
- Employees
- 75
- Next earnings
- —
About City Therapeutics, Inc.
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
- ISIN
- US1787821081
- Founded
- 2023
- Listed since
- Oct 16, 2026
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hangzhou Biotest Biotech Co.,Ltd.SHSE: 688767 | $860.61M | CN¥39.26 | +1.11% |
| Syndax Pharmaceuticals, Inc.NasdaqGS: SNDX | $858.87M | $9.54 | -0.52% |
| Seegene, Inc.KOSDAQ: A096530 | $841.38M | ₩24,650.00 | -1.79% |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd.SEHK: 2335 | $837.23M | HK$19.80 | -3.79% |
| Bambusa Therapeutics, Inc.NasdaqGS: BBTX | $814.06M | $15.98 | -0.68% |
| L&C BIO Co.,LTDKOSDAQ: A290650 | $813.06M | ₩20,150.00 | -6.06% |
| Aimed Bio Inc.KOSDAQ: A0009K0 | $802.22M | ₩16,500.00 | -9.89% |
| Rigel Pharmaceuticals, Inc.NasdaqGS: RIGL | $800.84M | $42.53 | -1.05% |